RCT: Effect of continued weekly subcutaneous Semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity
24 Mar, 2021 | 08:05h | UTCEffect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial – JAMA (free for a limited period)
Commentaries: Continuing Semaglutide Leads to Further Weight Loss – NEJM Journal Watch AND STEP 4: Long-term treatment needed for full semaglutide benefit – MedwireNews
Podcast: Semaglutide for Weight Loss – JAMA
Commentary on Twitter
In this RCT, weekly subcutaneous subcutaneous semaglutide resulted in increased weight loss over 48 weeks vs placebo in adults with #overweight or #obesity https://t.co/Ze6zHCG1Fd
— JAMA (@JAMA_current) March 23, 2021